European Commission Approves KEYTRUDA ® (pembrolizumab) for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who are Transplant-Ineligible and Have Failed BV

Dateline City:
KENILWORTH, N.J. First Approval for KEYTRUDA in a Hematologic Malignancy in the EUKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the European Commission has approved KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, for the treatment of
adult patients with relapsed or refractory classical Hodgkin lymphoma
(cHL)who have failed autologous stem cell transplant (ASCT) and
brentuximab vedotin (BV), or who are transplant-ineligible and have
failed BV.Language:
EnglishContact: MerckMedia:Pamela Eisele, [phone]orKim Hamilton, [phone]orInvestor:Teri Loxam, (908) 740-1986orAmy Klug, [phone]Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more

Source: Merck.com - Product News - May 5, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Classical Hodgkin Lymphoma Keytruda MSD NYSE:MRK Source Type: news